Clinical Trials Logo

Cervix Cancer clinical trials

View clinical trials related to Cervix Cancer.

Filter by:

NCT ID: NCT05764044 Not yet recruiting - Cervical Cancer Clinical Trials

Adjuvant Chemotherapy in cfHPV-DNA Plasma Positive Patients: A Biomarker In Locally Advanced Cervical Cancer

AddChemo
Start date: April 1, 2023
Phase: Phase 3
Study type: Interventional

This study hypothesizes that patients who persist with cell-free human papillomavirus deoxyribonucleic acid (cfHPV-DNA) plasma expression at the end of standard treatment, can derive the benefit of using adjuvant chemotherapy in locally advanced cervical cancer (CC). After standard treatment based on concomitant chemoradiotherapy regime, a qualitative and quantitative research of cfHPV-DNA in plasma of patients will be conducted. Those with a negative qualitative research result will leave the study. Patients who have positive research for plasma 16/18 cfHPV-DNA at the end of chemoradiotherapy treatment will be randomized to receive two additional cycles of adjuvant chemotherapy or observation. Patients will be followed with conduction of computed tomography (CT) scan of the thorax and magnetic resonance (MRI) of abdomen and pelvis and clinical and gynecological examination at every four months.

NCT ID: NCT05743517 Recruiting - Cervical Cancer Clinical Trials

Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)

Start date: September 15, 2023
Phase: N/A
Study type: Interventional

The primary purpose of the study is to determine which of four components (symptom-burden tailored app, exercise partner, oncology provider engagement, coaching) added to a core intervention of a wearable activity tracker and commercially available app, will improve physical activity. The findings will generate meaningful knowledge about how to best increase physical activity in older gynecologic cancer patients receiving systemic cancer therapies to improve quality of life and cancer-specific survival.

NCT ID: NCT05738902 Recruiting - Ovarian Cancer Clinical Trials

Adherence and Compliance to ERAS in Gynecological Surgery

ERASGYNBS002
Start date: May 30, 2023
Phase:
Study type: Observational

The aim of the study is to investigate the association between early non-compliance to ERAS in postoperative day 2 (POD2) with the rate of postoperative complications.

NCT ID: NCT05727228 Recruiting - Cervix Cancer Clinical Trials

Screening Triage and Risk Stratification

I-share
Start date: February 27, 2023
Phase:
Study type: Observational [Patient Registry]

- To investigate the performance of cytology, extended genotyping, p16/Ki67 dual stain cytology, DNA methylation and viral load as triage markers in post-menopausal HPV-screen-positive women aged 50-64 years in the organized screening program to predict the risk of developing CIN2+. (work package 1) - To investigate the performance of cytology, extended genotyping, p16/Ki67 dual stain cytology, DNA methylation and viral load six months after cervical excision to predict the long-term risk of residual/recurrent CIN2+ lesions among women aged 23-64 (work-package 2)

NCT ID: NCT05634681 Recruiting - Cervix Cancer Clinical Trials

Plan of the Day Radiotherapy

Start date: November 13, 2022
Phase: N/A
Study type: Interventional

The study objectives are to improve the treatment of LACC patients and to increase knowledge of the potential benefit of the plan-of-the-day concept on side effects during and after radiotherapy.

NCT ID: NCT05529303 Completed - Ovarian Cancer Clinical Trials

Prolonged Grief and Perception of Femininity in Gynecological Cancer Patients

Start date: February 26, 2023
Phase: N/A
Study type: Interventional

The aim of this study is to determine the effect of the 'Feminine Identity Improvement Program', based on cognitive behavioral and expressive techniques applied to gynecological cancer patients, on prolonged grief reactions and the perception of femininity. The study will be conducted in a randomized controlled and qualitative type with gynecological cancer patients who completed their surgical treatment at least three months ago in the last year at Afyonkarahisar Health Sciences University Hospital.

NCT ID: NCT05521997 Not yet recruiting - Cervical Cancer Clinical Trials

Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer

Start date: July 31, 2024
Phase: Phase 2
Study type: Interventional

Advanced cervical cancer patients treated with standard of care (SOC) chemoradiation plus glutaminase inhibition with telaglenastat (CB-839) will have increased progression-free survival (PFS) compared to historical rates for patients receiving SOC chemoradiation alone.

NCT ID: NCT05518253 Recruiting - Ovarian Cancer Clinical Trials

A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

Start date: May 30, 2022
Phase: Phase 1
Study type: Interventional

This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with CD70-positive advanced/metastatic solid tumors, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.

NCT ID: NCT05468190 Recruiting - Ovarian Cancer Clinical Trials

A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T

Start date: July 17, 2022
Phase: Phase 1
Study type: Interventional

As a phase I clinical research,this study plans to evaluate the safety and tolerability of CD70-targeting CAR-T cells in the treatment of CD70-positive advanced/metastatic solid tumors, and obtain recommended doses and infusion patterns.

NCT ID: NCT05448586 Completed - Breast Cancer Clinical Trials

Opioid Free Anaesthesia in Oncologic Gynaecological Surgery: Is There Any Benefit?

Start date: February 2, 2019
Phase:
Study type: Observational

Opioid Free Anesthesia (OFA) is a multimodal anesthesia and emerging technique that spares the use of opioids and involve other adjuvant anesthetics, which have demonstrated in vitro influence on immunologic and inflammatory response, as well as in metastatic progression. For these reasons we believe that OFA may positively influence in oncologic patients postoperative recovery and in its disease progression.